TJAB Forms Drug Development JV with Antisense of Australia
Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Technologies of Australia to develop a drug discovered by ANB. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma. TJAB will be responsible for marketing in China and Hong Kong, while ANB will retain those duties for the rest of the world. More details.... Stock Symbol: (ASX: ANB) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here